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Abstract
Background—Heavy alcohol consumption increases risk of developing squamous cell
carcinoma of the head and neck (SCCHN). Alcohol metabolism to cytotoxic and mutagenic
intermediates acetaldehyde and reactive oxygen species is critical for alcohol-drinking-associated
carcinogenesis. We hypothesized that polymorphisms in alcohol metabolism-related and
antioxidant genes influence SCCHN survival.
Methods—Interview and genotyping data (64 polymorphisms in 12 genes) were obtained from
1227 white and African-American cases from the Carolina Head and Neck Cancer Epidemiology
study, a population-based case–control study of SCCHN conducted in North Carolina from 2002
to 2006. Vital status, date and cause of death through 2009 were obtained from the National Death
Index. Kaplan–Meier log-rank tests and adjusted hazard ratios were calculated to identify alleles
associated with survival.
© 2013 Elsevier Ltd. All rights reserved.
*Corresponding author at: Texas Cancer Registry, Cancer Epidemiology and Surveillance Branch MC 1928, Department of State
Health Services, PO Box 149347, Austin, TX 78714-9347, USA. Tel.: +1 512 305 8094; fax: +1 847 589 2023.
ahakenewerth@gmail.com, anne.hakenewerth@dshs.state.tx.us. .
1Currently at Texas Cancer Registry, Department of State Health Services, PO Box 149347, Austin, TX 78714, USA.
2Dr. Millikan was closely involved in this research and approved the manuscript in dissertation form, but died before reviewing the
final manuscript.
Conflict of interest statement The authors have no financial or personal conflicts of interest to report.
NIH Public Access
Author Manuscript
Cancer Epidemiol. Author manuscript; available in PMC 2014 August 01.
Published in final edited form as:













Results—Most tested SNPs were not associated with survival, with the exception of the minor
alleles of rs3813865 and rs8192772 in CYP2E1. These were associated with poorer cancer-
specific survival (HRrs3813865, 95%CI = 2.00, 1.33–3.01; HRrs8192772, 95%CI = 1.62, 1.17–2.23).
Hazard ratios for 8 additional SNPs in CYP2E1, GPx2, SOD1, and SOD2, though not statistically
significant, were suggestive of differences in allele hazards for all-cause and/or cancer death. No
consistent associations with survival were found for SNPs in ADH1B, ADH1C, ADH4, ADH7,
ALDH2, GPx2, GPx4, and CAT.
Conclusions—We identified some polymorphisms in alcohol and oxidative stress metabolism
genes that influence survival in subjects with SCCHN. Previously unreported associations of SNPs
in CYP2E1 warrant further investigation.
Keywords
Head and neck neoplasms/epidemiology; Genes; Survival; Alcohol drinking/metabolism;
Oxidative stress
1. Introduction
Head and neck cancers typically include cancers of the oral cavity, pharynx, and larynx.
There were estimated to be 53,640 new cases and 11,520 deaths from oral cavity,
pharyngeal, and laryngeal cancers in the U.S. in 2013 [1]. Globally in 2008, oral cavity
tumors were among the top 10 incident cancers in men world-wide, and among the top 10
fatal cancers in men in developing countries [2]. Five-year relative survival for laryngeal,
oral cavity, and pharyngeal cancer patients averages about 80% for localized cases, 50% for
regional cases, and 33% for metastatic cases, with somewhat lower survival for laryngeal
compared to oral cavity and pharyngeal cancers [3]. Age-adjusted mortality rates for
African-American men with oral cavity and pharynx cancers are double those of men of
other races, and disparities are especially pronounced for men with laryngeal cancer (4.7
deaths per 100,000 population in African-Americans compared to 2.1 in whites, 1.9 in
Native Americans and Hispanics, and 0.7 in Asian/Pacific Islanders) [4].
It is estimated that 75% of new cases of SCCHN in the United States are caused by tobacco
use, especially cigarette smoking, and/or drinking of alcoholic beverages [5]. In the past few
decades the proportional incidence of oropharyngeal tumors associated with carcinogenic
human papillomavirus sub-types has risen; such tumors appear to have better prognosis than
non-HPV oropharyngeal tumors [6]. Multiple studies have reported associations between
SCCHN incidence and polymorphisms in alcohol metabolism genes, especially ADH1B,
ADH1C, ADH4, ADH7, ALDH2, and CYP2E1 [7–16]. The primary biological mechanism
responsible for this effect is hypothesized to be high levels of cytotoxic and mutagenic
acetaldehyde, the metabolic intermediate between ethanol and acetate. Acetaldehyde, when
associated with consumption of alcoholic beverages, is classified as a known human
carcinogen by the International Agency for Research on Cancer [17]. Also, alcohol
metabolism through CYP2E1, probably mediated by alcohol-induced stabilization of the
CYP2E1 protein [18], is known to result in production of increased levels of reactive oxygen
species (ROS) [19]. DNA damage by acetaldehyde or ROS has been suggested as one of the
key mechanisms of alcohol drinking-associated carcinogenesis, and variation in associated
pathway genes may modify progression and survival. Therefore, it is also of interest to know
whether polymorphisms in genes encoding enzymes protective against oxidative stress
(SOD, GPx, CAT) are associated with altered survival in SCCHN patients.
In addition to its role in alcohol metabolism, CYP2E1, as a member of the cytochrome P450
oxidative system, is involved in metabolism of xenobiotics and drugs [20], including the
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platinum-containing chemotherapeutic agents used to treat many head and neck cancers.
Although CYP2E1 enzymatically inactivates some substrates, it has also been shown to
bioactivate many compounds that are possibly carcinogenic; for example, the tobacco
carcinogen N-nitrosamines, 4-(methylnitrosamino)-1-(3-pyridyl)-1-buta-none [21].
While many studies have examined genetic associations with SCCHN incidence, there have
been few reports of the effect of gene polymorphisms in alcohol metabolism and oxidative
stress-related genes on survival of subjects with SCCHN. For example, only two studies
investigated whether selected ADH1C and CYP2E1 polymorphisms influence prognosis,
and they reported evidence of an association with advanced clinical stages or higher
recurrence [11,22]. Further, no studies have examined the influence on post-diagnosis
survival of genetic variation in the oxidative stress pathways.
We examined the effect on survival of 64 SNPs in ADH1B, ADH1C, ADH4, ADH7,
ALDH2, and CYP2E1 alcohol metabolism genes, and in CAT, GPx1, GPx2, GPx4, SOD1,
and SOD2 antioxidant genes, using exposure, genetic, clinical, and outcome data from cases
included in a large North Carolina (NC) population-based case–control study of SCCHN
that included both white and African-American subjects.
2. Materials and methods
2.1. Study population
Cases for this analysis were obtained from the Carolina Head and Neck Cancer
Epidemiology study (CHANCE), a population-based case–control study [23,24].
All cases of squamous cell carcinoma of the oral cavity, pharynx, and larynx diagnosed in
46 NC counties between January 1, 2002 and February 28, 2006 were eligible for
enrollment. Rapid identification of cases was conducted by the NC Central Cancer Registry
[24]. CHANCE cases included ICD-O-3 topography codes C0.00–C14.8, and C32.0–C32.9,
excluding salivary gland tumors (C07.9, C08.0–C08.9), nasopharynx (C11.0–C11.9), nasal
cavity (C30.0), and nasal sinuses (C31.0–C31.9). ICD-O-3 morphology codes included were
8010/3, 8051/3, 8083/3, 8071/3, 8072/3, 8073/3, 8074/3, and 8076/3. Benign tumors,
carcinomas in situ, papillary carcinomas, and adenoid carcinomas were excluded. This
analysis further excluded 21 lip cancers (C00.3–C00.9, C14.2), 26 cases of “other” race, and
115 without genotyping data, producing a study analysis group of 1227 cases, of which 922
were white/European-American and 305 were black/African-American.
Case tumors were classified into anatomic sub-site according to the following 5 ICD-O
categories that are also used by the International Head and Neck Cancer Epidemiology
(INHANCE) Consortium [25]: (1) oral cavity: C02.0–C02.3, C03.0, C03.1, C03.9, C04.0,
C04.1, C04.8, C04.9, C05.0, C06.0–C06.2, C06.8, and C06.9; (2) oropharynx: C01.9, C02.4,
C05.1, C05.2, C09.0, C09.1, C09.8, C09.9, C10.0–C10.4, C10.8, and C10.9; (3) oral cavity–
oropharynx–hypopharynx NOS: C02.8, C02.9, C05.8, C05.9, C14.0, C14.2, and C14.8; (4)
hypopharynx: C12.9, C13.0–C13.2, C13.8, and C13.9; and (5) larynx: C32.0–C32.3, and
C32.8–C32.9.
Written informed consent was obtained from all subjects. The study was approved by the
Biomedical Institutional Review Board at the University of North Carolina at Chapel Hill.
2.2. Outcome assessment
We determined whether death had occurred in study participants by December 31, 2009,
and, if so, the date and cause, through linkage with the United States National Death Index
(NDI). The NDI is a national file of identified death record information compiled from
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computer files submitted by State vital statistics offices [26]; of all US sources of national
death data, NDI has demonstrated the highest sensitivity and is the only national source with
a coded cause of death field suitable for research purposes [27]. CHANCE collected
multiple NDI matching data: social security number (SSN), date of birth (DOB), sex, race,
state of residence, and name. Therefore there was a high proportion (>75%) of perfect/very
close to perfect matches on SSN, DOB, and sex. The remaining near matches were further
confirmed by examining the United States Social Security Death Index, which is created
from Social Security Administration (SSA) records of persons with social security numbers
whose deaths were reported to the SSA, usually by mortuaries, attorneys, or family
members. A very small number were further confirmed by obituary search of newspaper
websites. Partial matches on name, but having in common only a few SSN digits and parts
of the DOB, that could not be confirmed by SSDI or obituary were excluded as non-
matches. If the initial three digits of the first-listed cause of death code were C01–C06, C09,
C10, C12–C14, or C32, the cause of death was classified as head and neck cancer.
2.3. SNP selection and genotyping
Blood samples were obtained at the time of questionnaire administration by nurse-
interviewers trained in phlebotomy. If the subject was not willing or able to consent to the
blood draw, they were asked to contribute a buccal cell sample via mouthrinse.
For this analysis, 75 SNPs (69 tag SNPs and 6 candidate SNPs found in prior studies to be
associated with aerodigestive cancer incidence, breast cancer survival, alcohol dependence,
or interaction with genes in the proposed carcinogenic pathway for vinyl chloride) were
selected in 12 genes that are part of two metabolic pathways: ADH1B, ADH1C, ADH4,
ADH7, ALDH2, and CYP2E1 in the alcohol metabolism pathway in the upper aerodigestive
tract; and CAT, SOD1, SOD2, GPx1, GPx2, and GPx4 in the oxidative stress metabolic
pathway. Tag SNPs, chosen to represent the genetic variation within each of the 12
candidate genes (gene and 2000 bp upstream and downstream) were selected using the
Genome Variation Server [28], using SNPs that were polymorphic in either CEU or YRI
HapMap Release 2 (unrelated only), and with the following parameters: allele frequency
cutoff 10%, 0.8 R2 threshold minimum for variations to belong to the same cluster, 85%
minimum data coverage for tag SNPs, 70% minimal data coverage for a variation to be
potentially clustered with others.
To control for potential population stratification, we selected 157 Ancestry Informative
Markers (AIMs) to maximize (1) the difference in allele frequencies (delta) between
European and African populations in the HapMap data (CEU versus YRI), and (2) the
Fisher’s information criterion (FIC). AIMs were prioritized based on having the highest
delta and FIC values in the following order: 90% European/10% African, 10% European/
90% African, and 50% European/50% African. This allowed AIMs to represent the entire
expected ancestral distribution of the study population. Individual estimates of percentage
African ancestry were calculated from 145 successfully genotyped AIMs using maximum
likelihood estimation (MLE) methods previously described [29–31]. AIMs were chosen to
differentiate only between African and European ancestry, so we derived individual ancestry
estimates for the two groups that summed to 1.0.
Genotyping was done by the Mammalian Genotyping Core Facility, University of North
Carolina at Chapel Hill, using the Illumina GoldenGate genotyping assay with Sentrix Array
matrix and 96-well standard microtiter plates. Technicians were blinded to case/control
status of samples, and samples from both cases and controls were tested on each plate, along
with DNA controls and random sample duplicates. Assay intensity data and genotype cluster
images for all SNPs were individually reviewed to identify those with inadequate signal
intensity or indistinguishable genotype clusters. Blind duplicates of 109 samples were
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genotyped to verify reliability of genotype calls. Tests of Hardy–Weinberg equilibrium
(HWE) were conducted in controls stratified by race, and those SNPs for which the p-value
was <0.001 were judged to be out of HWE.
DNA samples from 1266 CHANCE SCCHN cases of white or African-American race were
genotyped. Of these, 38 failed to genotype, and 1 was gender discrepant, leaving 1227 cases
with genotyping data. Of the 75 tag and candidate SNPs for which genotyping was
attempted, 8 tag SNPs and 1 candidate SNP were excluded from analyses due to inadequate
signal intensity or inability to distinguish genotype clusters, and 2 tag SNPs were excluded
due to genotypes being out of HWE at the p < 0.001 level, leaving 64 tag and candidate
SNPs available for analyses. Genotype calls for blind duplicates were concordant for all
SNPs. All 1227 cases had less than 4% missing SNP results.
2.4. Covariate measurement
Trained nurse-interviewers conducted an in-person interview with each subject. For this
analysis only self-reported, non-proxy data were included. Questions were asked about
demographics (age, sex, race-ethnicity, education, income, health insurance), cigarette
smoking, drinking of alcoholic beverages, diet, oral health, medical history, family history
of cancer, and textual information on co-morbid conditions.
We made an initial selection of covariates based on a priori knowledge regarding their
potential association with survival. Covariates obtained from the interview included age,
sex, race; duration of cigarette smoking; ever-use of non-cigarette tobacco products, ever
exposure to environmental tobacco smoke (ETS) at work, ever exposure to ETS at home;
whether the subject was covered by health insurance on diagnosis date, had a routine dental
visit in the past 10 years, ever had a loose permanent tooth due to disease, ever used
mouthwash; family history of SCCHN; household poverty as defined by federal guidelines
for both income and number of persons supported, highest attained education level; and
presence of selected co-morbid diseases: liver disease including hepatitis, cardiovascular
and/or lung disease, renal disease and/or diabetes, and other cancers. Alcohol consumption,
although measured, was not included in analyses because it may be an intermediate in the
causal pathway between some of the selected SNPs and survival.
Clinical information about the tumor and its treatment were abstracted from the subjects’
medical record. Pathology reports were reviewed by the study pathologist (WF) and a head
and neck cancer surgeon (MW). Tumor and treatment characteristics obtained included
TNM and summary stages, angiolymphatic invasion status, and cancer treatment (surgery,
radiation, and/or chemotherapy). These clinical-pathologic factors were chosen a priori as
potential confounders.
2.5. Statistical analysis
For all-cause death, months of survival were calculated by subtracting the date of diagnosis
from the date of death, and subjects who were still alive on 12/31/2009 were censored on
that date. For head-and-neck-cancer-specific death (hereafter referred to as cancer death or
cancer-specific death), months of survival were calculated by subtracting the date of
diagnosis from the date of cancer death, while subjects who died of another cause were
censored as of the date of death; subjects who were still alive on 12/31/2009 were censored
on that date. Kaplan–Meier survival plots, and hazard ratios for the independent effects of
SNPs from Cox proportional hazards regression models, were implemented in SAS® 9.2.
Kaplan–Meier plots and log-rank tests for all-cause and cancer-specific survival were
constructed for the two alleles of each SNP. Kaplan–Meier plots and log-rank tests were also
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constructed for all-cause and cancer specific survival for the two races, for all head-and-
neck cancers combined as well as separately for each anatomic sub-site.
A dominant genetic model (at least one minor allele versus referent of no minor alleles) was
implemented because, for many of the SNPs, the number of subjects homozygous for the
minor allele was too small to permit estimation of precise effect measure estimates.
Potential covariates were selected using a step-wise backwards elimination from a full
model (which contained demographic, socioeconomic status (SES), tumor, clinical, co-
morbid diseases, oral health, and tobacco exposure variables, as listed in Table 2) and
comparison of each reduced model to the full model. There was no collinearity between any
of the explanatory variables except possibly between race and ancestry. If eliminating a set
of covariates did not change the ln(HR) for any SNP by a difference of at least 0.10, those
covariates were eliminated from subsequent models. The final Cox models for all-cause and
cancer-specific death included the demographic, SES, tumor, clinical, co-morbid diseases,
oral health, and tobacco exposure variables listed in Table 3 footnotes. With self-reported
race included in the model the ancestry variable was not important to all-cause or cancer-
specific death for the genetic variants studied, so for parsimony, and because ancestry and
race showed evidence of collinearity, ancestry was not included in final models.
For head and neck cancer, clinicians consider local-regional-distant stage classification to be
inadequate for predicting survival; for example, advanced nodal (N) stage is a worse
prognosticator than advanced locus disease [32,33]. Therefore, recent studies of survival in
head and neck cancer patients most often control for cancer stage in Cox regression models
by including separate variables representing tumor (T), node (N), and metastasis (M) stages.
In CHANCE, comparison of two sets of hazard ratios and confidence intervals from Cox
regression models that included summary stage, versus models that included separate
variables for T, N, and M stages, revealed similar estimates from both methods. Therefore
we controlled for stage using three separate variables.
In order to include available information from all cases, and because the data were not
missing in a monotone pattern, we used the Markov Chain Monte Carlo method
implemented in SAS® 9.2 PROC MI and information about non-missing values from all
variables in full models (i.e. all variables in Table 2) to impute missing values for variables
included in final models. This method imputes missing values for binary variables (such as
angiolymphatic invasion) as continuous values from a normal distribution, which we did not
round to 0 or 1 because the continuous values are less biased. Hazard ratios reported from
those analyses are summaries of HRs from Cox regressions using 25 imputed datasets,
calculated using SAS® 9.2 PROC MIANALYZE.
To adjust for Type 1 error due to multiple statistical tests for 64 SNPs, we compared results
using three methods of correction: Bonferroni, False Discovery Rate, and False Positive
Report Probability. Because results and conclusions were essentially the same from all three
models, the simplest and most commonly-used method – Bonferroni – was used to correct p-
values.
3. Results
Mean and median follow-up times from diagnosis date through 12/31/2009 were 71.2 and
70.6 months, respectively. As of December 31, 2009, 545 of 1227 cases (44%) had died, of
which 227 (42%) died of head and neck cancer. Mean survival in all subjects with SCCHN
was 52.5 months (Table 1). Mean/median survival for those with hypopharynx tumors was
lower (39/30 months) than for those with other tumor sites (49–55/53–58 months). For
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subjects who died during the follow-up period, mean/median survival for all-cause death
was 30.2/25.1 months, and for cancer-specific death, 24.0/19.5 months.
Descriptive analyses. Table 2 presents the frequency distributions and hazard ratios for the
initial set of covariates within the study population.
For both all-cause and cancer-specific survival, more subjects with oropharynx cancer
survived compared to those with oral cavity and hypopharynx tumors (Table 2). Improved
survival was also associated with: lower tumor and node stages, absence of angiolymphatic
invasion, surgical cancer treatment, and shorter duration of smoking. In addition, having
survived was also associated with being younger, richer, more educated, having health
insurance, and having had at least one routine dental visit in the last 10 years. African-
American race was associated with all-cause death but not cancer-specific death in
univariate analysis.
SNP hazard ratios and survival plots. Backwards elimination of potential covariates, from 64
full models each containing one SNP (of the 64 studied) and all covariates listed in Table 2,
produced a Cox regression model for all-cause death containing the following covariates:
SNP being analyzed (one per model); anatomic subsite; T, N, and M stage; angiolymphatic
invasion status; treatment (surgery, chemotherapy); co-morbid cardiovascular or lung
disease; duration of cigarette smoking; and routine dental care. The final Cox regression
model for cancer death contained all those variables, plus radiation treatment, co-morbid
liver disease, sex, race, age category, federal poverty group, exposure to ETS at work, and
tooth mobility due to disease.
In unadjusted analyses, most SNPs were not associated with significantly increased hazard
of all-cause or cancer death (Table 3), and results were generally consistent between models.
However, two SNPs in CYP2E1–rs3813865 and rs8192772 – were associated with
increased hazard of cancer death after adjustment for confounders in complete-case analysis
and Bonferroni correction of p-values, with a similar pattern noted after adjustment for
confounders in multiple imputation analysis (Table 3). Carrying the ‘C’ minor allele of
rs3813865 was associated with double the hazard of head and neck cancer death compared
to the ‘G’ allele (plog-rank = 0.008). Similarly, carrying the ‘C’ minor allele of rs8192772
was associated with about 60% increased cancer death hazard compared to the ‘T’ allele
(plog-rank = 0.004). A non-statistically significant association with higher hazard of cancer
death was noted in unadjusted Cox regression models (Table 3) and in the p-values (0.008,
0.004) for Kaplan–Meier survival curves for these SNPs (Fig. 1). A non-significant increase
in hazard of all-cause death was also noted for these SNPs, due to the association with
cancer death (data not shown).
Most SNPs had similar survival effects in both African-Americans and whites, though there
were suggestive differences for some SNPs (Table 4). Low allele frequencies in one race or
the other precluded precise evaluation of statistical differences. For example, carrying the
CYP2E1 rs3813865 minor ‘C’ allele, present in 26% of African-Americans and 5% of
whites, conferred an increased HR (95% CI) in all subjects of 2.0 (1.3–3.0), which was 2.6
(1.5–4.9) in African-Americans, and 1.4 (0.7–2.7) in whites. Carrying the minor ‘C’ allele of
rs8192772, present in 22% of African-Americans and 14% of whites, conferred similar
increased risks in blacks and whites, with a HR (95% CI) of 1.6 (1.2–2.2) in all subjects, 1.9
(1.0–3.6) in African-Americans, and 1.5 (1.0–2.2) in whites.
Three additional SNPs in CYP2E1 (rs7092584, rs743535, rs2249695), and five SNPs in the
oxidative stress pathway (rs11623705 and rs2412065 in GPx2, rs10432782 and rs2070424
in SOD1, and rs2842980 in SOD2) displayed suggestive differences in allele hazards for
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either or both all-cause and cancer death from Kaplan–Meier and log-rank analysis (Table
4).
Examination of hazard ratios stratified by summary stage (Table 5) indicate that carriers of
the ‘C’ minor allele of rs3813865 in CYP2E1 experienced higher hazard of death compared
to those homozygous for the major allele, for tumors diagnosed at stage II/III and stage IV.
In contrast, higher hazard of death was limited to patients with Stage II/III tumors (not Stage
IV) carrying the minor allele of rs8192772 in CYP2E1, rs7092584 in CYP2E1, rs11623705
in GPx2, rs2070424 in SOD1, or rs2842980 in SOD2.
Table 6 presents hazard ratios for each genotype and chemotherapy combination for the 11
SNPs in Tables 4 and 5, using a common referent group for each SNP consisting of those
homozygous for the major allele who did not receive chemotherapy. Among those who did
not receive chemotherapy, the minor alleles of four CYP2E1 SNPs (rs3813865, rs8192772,
rs7092584, rs743535) were associated with greater hazard of both all-cause and cancer
death, and two SNPs in GPx2 (rs11623705, rs2412065) were associated with cancer death
(not all-cause). In those who received chemotherapy, carriers of the minor allele had HR
point estimates similar to those homozygous for the major allele (i.e. both were less than
1.0) but they were not statistically different.
To investigate the effect of including alcohol consumption and percent African ancestry
variables to the final reduced models, hazard ratios were re-calculated with those variables
included. Effect estimates changed very little, if at all (data not shown).
4. Discussion
In this study we evaluated the association of SNPs in genes in alcohol metabolism and
oxidative stress pathways with survival after SCCHN diagnosis. Overall, we found that most
SNPs were not associated with survival. However, we found that the minor alleles of two
SNPs in CYP2E1 were significantly associated with increased hazard for death from head
and neck cancer, especially in Stage II/III tumors. Also, carrying the minor allele of these
SNPs was associated with worse survival only in those who did not receive chemotherapy.
In contrast, having received chemotherapy was associated with improved survival regardless
of genotype, although improvement was not statistically significant in carriers of the minor
allele.
CYP genes are highly conserved, yet some polymorphisms have been found to be associated
with cancer risk and survival. For example, RsaI/rs2031920 and a 96-bp insertion
polymorphism in CYP2E1 have been associated with incidence of colorectal and esophageal
cancer [21]. It is thought that these effects are produced by CYP2E1 inducibility rather than
enzyme function, primarily by a mechanism that stabilizes the protein against degradation
[34]. One study suggested that CYP2E1 polymorphisms play a role in the metabolism of
drugs used to treat non-Hodgkin lymphoma, with one allele of rs2070673 associated with
longer survival [35], and another reported a significant association between CYP2E1
rs2031920 wild-type ‘C’ allele and improved survival from non-small cell lung cancer [36].
Our findings provide evidence that two CYP2E1 gene polymorphisms are associated with
survival from head and neck cancer; carriers of the minor allele of these SNPs experienced
worse survival than those homozygous for the major allele. This effect appeared only in
those who did not receive chemotherapy, which if true, implies that these SNPs do not affect
CYP2E1 metabolism of, or induction by, platinum-containing chemotherapeutic agents. The
effect did not appear to differ between those who received radiation therapy and those who
did not (data not shown). Similar to other studies reporting that apparently non-functional
CYP2E1 SNPs influence cancer risk, the two SNPs we identified with the highest survival
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associations are also in typically non-coding regions of the genome – rs3813865 in the 5′
region near the gene, and rs8192772 in intron 2. Interestingly, some studies have suggested
that upstream 5′ mutations in CYP2E1 may affect gene expression and inducibility by
ethanol [37]. If these SNPs are not causal, they may instead be in linkage disequilibrium
with a causal polymorphism.
Although one previous study reported an association of CYP2E1 rs2031920 with advanced
T stage SCCHN [11], ours is the first study to report the association of SNPs in CYP2E1
with survival after SCCHN diagnosis. Effects were observed in both unadjusted models and
those adjusted for covariates that are independently associated with survival, suggesting that
the association between SNP and survival is independent of other factors. Our results are
compatible with the hypothesis that genetic predisposition affects cancer-specific survival
after diagnosis, an effect which appears to be at least partly ameliorated by platinum-
containing chemotherapeutic agents. Although results for a few other SNPs in other genes in
the oxidative stress pathway suggested possible survival differences between genotypes,
none were statistically significant, and no SNPs in other alcohol metabolism genes
(ADH1B, ADH1C, ADH4, ADH7, ALDH2) were associated with either cancer-specific or
overall survival.
CHANCE is one of the largest population-based studies of head and neck cancer ever
conducted in the United States, and its population is drawn from a racially diverse region,
resulting in the largest number of African-Americans ever enrolled in a molecular
epidemiologic study of head and neck cancer. We were also able to adjust for population
stratification by using ancestry informative markers. Unfortunately, the number of African-
American participants (n = 305) was too small to provide sufficient power to adequately
assess racial differences in SNP associations with survival. We studied mostly tag SNPs in
order to study polymorphism associations with cancer across entire genes. We used a minor
allele frequency threshold of 10% or greater, so we were unable to examine rare variants.
Outcome assessment using high-quality identifying variables to link with the gold standard
NDI to obtain vital status and cause of death is a strength of our study; any residual errors in
determining vital status would tend to drive observed associations nearer the null. While
CHANCE obtained detailed information on well-known risk factors such as smoking and
drinking, and on many minor risk factors, it did not assess human papillomavirus (HPV)
infection. The association of HPV with our SNPs would likely be minimal. If survival
effects due to SNP polymorphisms are more pronounced in subjects with rapidly-fatal
disease. It is possible that study subjects excluded from analysis because they died soon after
diagnosis and before providing a biological sample (n = 52) could have biased our results
toward the null. However, we found no evidence of SNP associations with T, N, or summary
stage in our data. Although it is possible that our results could be due to chance, the effects
persist even after Bonferroni adjustment for multiple comparisons, so we do not feel this is a
likely explanation of our findings. In addition, we did not have any data on locoregional
recurrence or distant metastasis.
In conclusion, our study found multiple SNPs in CYP2E1 to be statistically associated with
cancer-specific survival, but only in those who did not receive chemotherapy. Future genetic
factors and survival analyses of head and neck cancer should confirm the association with
these SNPs and refine the identification of potentially causal loci in larger and diverse study
populations. Such research would improve understanding of differential treatment effects on
head and neck tumor progression and metastasis.
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Table 1
Survivala within study population.
Survival (months)
n Mean 25th percentile 50th percentile 75th percentile
All subjects 1227 52.5 29.2 56.3 73.7
 Oral cavity 172 49.0 23.2 52.6 71.2
 Oropharynx 333 54.7 33.7 58.0 76.4
 Hypopharynx 55 39.0 16.3 30.0 65.3
 Oral cavity–oropharynx–hypopharynx NOS 224 51.4 22.8 57.1 74.5
 Larynx 443 54.3 36.1 56.9 74.3
Subjects who died of any cause 545 30.2 13.8 25.1 42.9
Subjects who died of head and neck cancer 227 24.0 12.5 19.5 32.0
a
Vital status as of 31/12/2009, as determined from NDI.
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Table 2
Descriptives and univariate hazard ratios for non-SNP variables – one explanatory variable per model
(complete case analysis).
Death from all causes (n = 545) Death from head and neck cancer (n =227)
Potential covariate (type) Covariate values # (%) of
total cases
# Died/










Age category (ordinal) 20–49 years 239 (19.5%) 87/152 1.10 (1.05–1.15) 2.1E-05 42/197 1.08 (1.00–1.15) 0.043
50–54 years 189 (15.4%) 79/110 30/159
55–59 years 207 (16.9%) 82/125 35/172
60–64 years 205 (16.7%) 87/118 37/168
65–69 years 168 (l3.7%) 90/78 33/135
70–74 years 135 (11.0%) 71/64 27/108
75–80 years 84 (6.8%) 49/35 23/61
Sex (categorical) Female 289 (23.6%) 126/163 1.00 (ref) 58/231 1.00 (ref)
Male 938 (76.4%) 419/519 1.04 (0.85–1.27) 0.678 169/769 0.91 (0.68–1.23) 0.551
Race (categorical) White/European-American 922 (75.1%) 383/539 1.00 (ref) 169/753 1.00 (ref)
Black/African-American 305 (24.9%) 162/143 1.42 (1.18–1.71) 1.8E-04 58/247 1.14 (0.84–1.53) 0.403
Proportion African ancestry
(continuous) (mean % in those who
died)
1227 0.27/0.21 1.64 (1.28–2.10) 1.0E-04 0.24/0.24 1.19 (0.79–1.79) 0.401
Tumor/treatment characteristics
Anatomic subsite (categorical) Oral cavity (referent) 172 (14.0%) 91/81 1.00 (ref) 38/134 1.00 (ref)
Hypopharynx 55 (4.5%) 39/16 1.66 (1.14–2.41) 0.009 15/40 1.46 (0.80–2.65) 0.215
Larynx 443 (36.1%) 197/246 0.76 (0.59–0.97) 0.027 78/365 0.72 (0.49–1.07) 0.103
Oral cavity–oropharynx– 224 (18.3%) 90/134 0.73 (0.54–0.97) 0.033 42/182 0.83 (0.53–1.28) 0.393
hypopharynx NOS
Oropharynx 333 (27.1%) 128/205 0.65 (0.50–0.86) 0.002 54/279 0.67 (0.44–1.02) 0.062
T stage (ordinal) T1, T1a, T1b 392 (31.9%) 125/267 1.38 (1.28–1.49) 1.9E-16 34/358 1.62 (1.43-1.82) 2.2E-15
T2 409 (33.3%) 177/232 74/335
T3 218 (17.8%) 119/99 55/163
T4, T4a, T4b 208 (17.0%) 124/84 64/144
N stage (ordinal) N0 657 (53.5%) 261/396 1.26 (1.16–1.37) 5.2E-08 90/567 1.47 (1.30–1.68) 2.6E-09
N1 156 (12.7%) 67/89 33/123
N2, N2a, N2b, N2c 366 (29.8%) 184/182 83/283
N3 48 (3.9%) 33/15 21/27
M stage (categorical) M0 1219 (99.3%) 538/681 1.00 (ref) 222/997 1.00 (ref)
M1 8 (0.7%) 7/1 6.95 (3.28–14.70) 4.0E-07 5/3 10.19 (4.18–24.88) 3.4E-07
Margin status (categorical) Negative 396 (32.3%) 170/226 1.00 (ref) 65/331 1.00 (ref)
Positive 691 (56.3%) 317/374 1.12 (0.93–1.35) 0.233 137/554 1.25 (0.93–1.68) 0.141
Missing 140 (11.4%) 58/82 25/115
Angiolymphatic invasion (Categorical) Absent 954 (77.8%) 412/542 1.00 (ref) 171/783 1.00 (ref)
Present 107 (8.7%) 58/49 1.48 (1.12–1.94) 0.006 26/81 1.54 (1.02–2.33) 0.039
Missing 166 (13.5%) 75/91 30/136
Surgical treatment (categorical) No 537 (43.8%) 268/269 1.00 (ref) 119/418 1.00 (ref)
Yes 690 (56.2%) 277/413 0.72 (0.61–0.85) 1.2E-04 108/582 0.64 (0.50–0.84) 0.001
Radiation treatment (categorical) No 282 (23.0%) 105/177 1.00 (ref) 37/245 1.00 (ref)
Yes 945 (77.0%) 440/505 1.36 (1.10–1.68) 0.005 190/755 1.63 (1.15–2.32) 0.007
Chemotherapy treatment (categorical) No 754 (61.5%) 326/428 1.00 (ref) 130/624 1.00 (ref)
Yesb 473 (38.5%) 219/254 1.15 (0.97–1.36) 0.111 97/376 1.26 (0.97–1.63) 0.090
Comorbid diseases
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Death from all causes (n = 545) Death from head and neck cancer (n =227)
Potential covariate (type) Covariate values # (%) of
total cases
# Died/









Comorbid liver disease and/or hepatitis
(categorical)
No 1113 (90.7%) 476/637 1.00 (ref) 198/915 1.00 (ref)
Yes 105 (8.6%) 63/42 1.62 (1.24–2.10) 3.4E-04 25/80 1.47 (0.97–2.24) 0.067
Missing 9 (0.7%) 6/3 4/5
Comorbid cardiovascular and/or lung
disease (categorical)
No 887 (72.3%) 357/530 1.00 (ref) 153/734 1.00 (ref)
Yes 336 (27.4%) 186/150 1.47 (1.24–1.76) 1.8E-05 72/264 1.31 (0.99–1.73) 0.061
Missing 4 (0.3%) 2/2 2/2
Comorbid renal disease and/or diabetes
(categorical)
No 1053 (85.8%) 451/602 1.00 (ref) 196/857 1.00 (ref)
Yes 167 (13.6%) 88/79 1.32 (1.05–1.66) 0.018 28/139 0.97 (0.65–1.44) 0.873
Missing 7 (0.6%) 6/1 3/4
Comorbid disease: other cancer
(categorical)
No 1019 (83.0%) 446/573 1.00 (ref) 186/833 1.00 (ref)
Yes 204 (16.6%) 96/108 1.08 (0.87–1.35) 0.477 38/166 1.02 (0.72–1.44) 0.932
Missing 4 (0.3%) 3/1 3/1
# Comorbid conditions (continuous)
(mean # in those who died)
1227 1.03/0.72 1.24 (1.14–1.34) 1.2E-07 0.95/0.84 1.13 (1.00–1.29) 0.051
Other potential confounders
Smoking duration, rounded to nearest
whole year (continuous)
1227 36.9/27.9 1.02 (1.02–1.03) 3.5E-16 36.4/30.9 1.02 (1.01–1.03) 4.2E-06
 (mean # years in those who died)
Alcoholic beverages, lifetime
consumption of ethanol in ml,
Never-drinkers 117 (9.5%) 38/79 1.00 (ref) 20/97 1.00 (ref)
 never-users and tertiles of drinking >0–133,294 210 (17.1%) 61/149 0.84 (0.56–1.27) 0.413 28/182 0.75 (0.42–1.33) 0.324
133,294–757,550 318 (25.9%) 129/189 1.24 (0.86–1.78) 0.251 50/268 0.90 (0.53–1.51) 0.683
757,550+ 505 (41.2%) 277/228 1.94 (1.38–2.73) 1.0E-04 113/392 1.45 (0.90–2.33) 0.126
Missing 77 (6.3%) 40/37 16/61
Federal poverty guideline (categorical) At or above 816 (66.5%) 307/509 1.00 (ref) 135/681 1.00 (ref)
Below 356 (29.0%) 208/148 1.87 (1.56–2.23) 4.1E-12 78/278 1.53 (1.16–2.03) 0.003
Missing 55 (4.5%) 30/25 14/41
Routine dental visit in last 10 years
(categorical)
Yes 781 (63.7%) 278/503 1.00 (ref) 127/664 1.00 (ref)
No 438 (35.7%) 262/176 2.01 (1.70–2.38) 5.1E-16 97/341 1.59 (1.22–2.07) 0.001
Missing 8 (0.7%) 5/3 3/5
Environmental tobacco smoke
exposure at home (categorical)
No 399 (32.5%) 148/251 1.00 (ref) 62/337 1.00 (ref)
Yes 827 (67.4%) 396/431 1.36 (1.12–1.64) 0.001 164/663 1.33 (0.99–1.78) 0.056
Missing 1 (0.1%) 1/0 1/0
Environmental tobacco smoke No 316 (25.8%) 153/163 1.00 (ref) 64/252 1.00 (ref)
exposure at work (categorical) Yes 909 (74.1%) 391/518 0.85 (0.70–1.02) 0.078 162/747 0.84 (0.63–1.13) 0.246
Missing 2 (0.2%) 1/1 1/1
Ever used non-cigarette tobacco product
(categorical)
No 754 (61.5%) 329/425 1.00 (ref) 136/618 1.00 (ref)
Yes 473 (38.5%) 216/257 1.07 (0.90–1.26) 0.469 91/382 1.09 (0.83–1.42) 0.545
Had health insurance on reference date
(categorical)
Yes 1068 (87.0%) 459/609 1.00 (ref) 188/880 1.00 (ref)
No 154 (12.6%) 82/72 1.43 (1.13–1.81) 0.003 37/117 1.54 (1.08–2.19) 0.016
Missing 5 (0.4%) 4/1 2/3
Highest education level attained
(categorical)
High school or more 828 (67.5%) 325/503 1.00 (ref) 140/688 1.00 (ref)
Less than high school 399 (32.5%) 220/179 1.58 1.33–1.87) 1.7E-07 87/312 1.42 (1.09–1.86) 0.010
Ever had loose permanent tooth due to
disease (categorical)
No 765 (62.3%) 308/457 1.00 (ref) 146/619 1.00 (ref)
Yes 455 (37.1%) 232/223 1.35(1.14–1.60) 0.001 78/377 0.94 (0.71-1.23) 0.639
Missing 7 (0.6%) 5/2 3/4
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Death from all causes (n = 545) Death from head and neck cancer (n =227)
Potential covariate (type) Covariate values # (%) of
total cases
# Died/









Ever regularly used mouthwash
(categorical)
No 502 (40.9%) 216/286 1.00 (ref) 88/414 1.00 (ref)
Yes 719 (58.6%) 324/395 1.07 (0.90–1.27) 0.469 137/582 1.11 (0.85–1.45) 0.462
Missing 6 (0.5%) 5/1 2/4
Family history of H and N cancer in 1st
degree relatives (categorical)
No 1206 (98.3%) 535/671 1.00 (ref) 222/984 1.00 (ref)
Yes 21 (1.7%) 10/11 1.11 (0.59–2.08) 0.742 5/16 1.31 (0.54–3.18) 0.551
a
For categorical variables, HRs are in comparison to referent category. For continuous and ordinal variables, HRs are per unit of measurement and
are cumulative (e.g. HR per year of age, HR per each additional comorbid disease, HR per each higher stage category).
b
Of 473 cases who received chemotherapy, 464 (98%) received at least one platinum-containing agent.
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Table 5
Selected SNP hazard ratios of death from head and neck cancer, stratified by summary AJCC stagea (models
and covariates as in Table 5).















CYP2E1 rs3813865 G/C 251/28 – 382/49 2.80(1.45–5.44) 469/48 2.18 (1.23–3.88)
rs8192772 T/C 240/39 1.47 (0.38–5.69) 358/73 1.89 (1.10–3.26) 428/88 1.40 (0.90–2.18)
rs7092584 C/T 227/52 0.95 (0.25–3.67) 337/93 1.77 (1.06–2.96) 398/118 0.97 (0.64–1.47)
rs743535 C/T 227/51 1.70 (0.50–5.80) 340/87 1.52 (0.88–2.60) 402/111 1.29 (0.86–1.94)
rs2249695 C/T 156/123 0.73 (0.22–2.37) 217/213 1.48 (0.89–2.46) 250/267 1.25 (0.84–1.88)
GPx2 rs11623705 G/T 229/50 1.49 (0.43–5.10) 348/83 1.78 (1.04–3.05) 423/94 1.31 (0.84–2.06)
rs2412065 G/C 163/116 1.25 (0.41–3.83) 245/186 1.32 (0.82–2.13) 290/227 1.32 (0.91–1.92)
SOD1 rs10432782 T/G 211/68 1.05 (0.31–3.53) 297/133 1.54 (0.95–2.47) 368/149 0.98 (0.66–1.46)
rs2070424 A/G 240/39 0.35 (0.04–2.85) 342/89 1.81 (1.08–3.04) 423/94 1.10 (0.69–1.76)
SOD2 rs2842980 A/T 174/105 1.67 (0.59–4.72) 245/186 1.77 (1.11–2.83) 298/219 1.40 (0.97–2.03)
a
SNPs were selected for presentation in this table if the confidence interval for the adjusted HR and the Kaplan–Meier log-rank p-value both
appeared to depart from the null, for either all-cause or cancer-specific death, or both.
b
Cox models used to calculate hazard ratios for head and neck cancer-specific death included SNP coded for dominant model (any minor allele
versus homozygous major allele), age, sex, race, anatomical site, T stage, N stage, M stage, angiolymphatic invasion status, surgical treatment,
chemotherapy treatment, radiation treatment, presence of comorbid cardiovascular or lung disease, presence of comorbid liver disease or hepatitis,
duration of smoking cigarettes (years), ever exposure to environmental tobacco smoke at work, reception of at least one routine dental visit in past
10 years, ever loss of a tooth due to disease, federal poverty level. 25 datasets were imputed, and results were summarized as a single HR.
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Table 6
Analysis of interaction between selected SNPsa and platinum chemotherapy treatment.
All-cause death Cancer death





























GG 295/398 1.00 (ref) 180/229 0.67 (0.51–0.87) 114/579 1.00 (ref) 81/328 0.55 (0.35–0.86)
GC + CC 37/33 1.40 (0.97–2.02) 33/22 0.92 (0.61–1.40) 18/52 2.34 (1.30–4.23) 14/41 1.13 (0.58–2.20)
rs8192772
TT 270/378 1.00 (ref) 167/211 0.67 (0.50–0.88) 101/547 1.00 (ref) 77/301 0.64 (0.40–1.01)
TC + CC 61/53 1.50 (1.11–2.01) 46/40 0.88 (0.61–1.29) 31/83 2.34 (1.50–3.66) 18/68 0.80 (0.43–1.50)
rs7092584
CC 256/352 1.00 (ref) 155/199 0.66 (0.49–0.87) 96/512 1.00 (ref) 73/281 0.61 (0.38–0.97)
CT + TT 74/79 1.22 (0.92–1.60) 58/52 0.83 (0.58–1.18) 35/118 1.44 (0.93–2.24) 22/88 0.70 (0.39–1.26)
rs743535
CC 251/356 1.00 (ref) 164/198 0.70 (0.53–0.93) 94/513 1.00 (ref) 73/289 0.61 (0.39–0.98)
CT + TT 79/72 1.34 (1.02–1.77) 47/51 0.72 (0.49–1.05) 37/114 1.62 (1.04–2.52) 21/77 0.66 (0.35–1.23)
rs2249695
CC 161/239 1.00 (ref) 85/138 0.58 (0.41–0.82) 60/340 1.00 (ref) 41/182 0.50 (0.28–0.88)
CT + TT 171/192 1.01 (0.79–1.28) 128/112 0.77 (0.56–1.06) 72/291 1.30 (0.84–2.00) 54/186 0.80 (0.47–1.36)
GPx2 rs11623705
GG 268/347 1.00 (ref) 185/200 0.70 (0.53–0.91) 96/519 1.00 (ref) 77/308 0.62 (0.40–0.97)
GT + TT 64/84 0.99 (0.73–1.34) 28/51 0.54 (0.34–0.85) 36/112 1.63 (1.02–2.61) 18/61 0.70 (0.36–1.37)
rs2412065
GG 172/252 1.00 (ref) 122/152 0.69 (0.51–0.93) 59/365 1.00 (ref) 56/218 0.72 (0.43–1.20)
GC + CC 160/179 1.03 (0.82–1.31) 91/99 0.68 (0.49–0.95) 73/266 1.55 (1.03–2.33) 39/151 0.68 (0.39–1.19)
SOD1 rs10432782
TT 227/318 1.00 (ref) 144/187 0.69 (0.52–0.92) 89/456 1.00 (ref) 63/268 0.53 (0.33–0.86)
TG + GG 105/113 1.19 (0.92–1.53) 69/63 0.74 (0.53–1.04) 43/175 1.16 (0.76–1.78) 32/100 0.72 (0.42–1.24)
rs2070424
AA 267/365 1.00 (ref) 161/212 0.66 (0.50–0.86) 105/527 1.00 (ref) 70/303 0.52 (0.33–0.82)
AG + GG 65/66 1.08 (0.80–1.46) 52/39 0.77 (0.54–1.11) 27/104 0.96 (0.57–1.63) 25/66 0.73 (0.41–1.29)
SOD2 rs2842980
AA 178/266 1.00 (ref) 121/152 0.67 (0.49–0.90) 67/377 1.00 (ref) 46/227 0.49 (0.29–0.82)
AT + TT 154/165 1.06 (0.84–1.34) 92/99 0.73 (0.53–1.01) 65/254 1.23 (0.83–1.84) 49/142 0.85 (0.50–1.44)
a
SNPs were selected for presentation in this table if the confidence interval for the adjusted HR and the Kaplan–Meier log-rank p-value both
appeared to depart from the null, for either all-cause or cancer-specific death, or both.
b
Cox models used to calculate hazard ratios for all-cause death included SNP coded for dominant model (any minor allele versus homozygous
major allele), anatomical site, T stage, N stage, M stage, angiolymphatic invasion status, treatment (surgery), presence of comorbid cardiovascular
or lung disease, duration of smoking cigarettes (years), reception of at least one routine dental visit in past 10 years. 25 datasets were imputed, and
results were summarized as a single HR.
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c
Cox models used to calculate hazard ratios for cancer-specific death included SNP coded for dominant model (any minor allele versus
homozygous major allele) and all covariates listed above for all-cause death models, plus the following additional variables: radiation treatment,
presence of comorbid liver disease or hepatitis, sex, race, age, federal poverty level, ever exposure to environmental tobacco smoke at work, ever
loss of a tooth due to disease. 25 datasets were imputed, and results were summarized as a single HR.
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